86 related articles for article (PubMed ID: 24881568)
1. Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus.
Defossa E; Wagner M
Bioorg Med Chem Lett; 2014 Jul; 24(14):2991-3000. PubMed ID: 24881568
[TBL] [Abstract][Full Text] [Related]
2. Oral Nano Drug Delivery Systems for the Treatment of Type 2 Diabetes Mellitus: An Available Administration Strategy for Antidiabetic Phytocompounds.
Nie X; Chen Z; Pang L; Wang L; Jiang H; Chen Y; Zhang Z; Fu C; Ren B; Zhang J
Int J Nanomedicine; 2020; 15():10215-10240. PubMed ID: 33364755
[TBL] [Abstract][Full Text] [Related]
3. Predicting GPR40 Agonists with A Deep Learning-Based Ensemble Model.
Yang J; Jiang C; Chen J; Qin LP; Cheng G
ChemistryOpen; 2023 Nov; 12(11):e202300051. PubMed ID: 37404062
[TBL] [Abstract][Full Text] [Related]
4. Natural products with potential hypoglycemic activity in T2DM: 2019-2023.
Fei Z; Xu Y; Zhang G; Liu Y; Li H; Chen L
Phytochemistry; 2024 Jul; 223():114130. PubMed ID: 38714289
[TBL] [Abstract][Full Text] [Related]
5. The G-Protein-Coupled Long-Chain Fatty Acid Receptor GPR40 and Glucose Metabolism.
Tomita T; Hosoda K; Fujikura J; Inagaki N; Nakao K
Front Endocrinol (Lausanne); 2014; 5():152. PubMed ID: 25309513
[TBL] [Abstract][Full Text] [Related]
6. GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit.
Mancini AD; Poitout V
Diabetes Obes Metab; 2015 Jul; 17(7):622-9. PubMed ID: 25604916
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial.
Kaku K; Enya K; Nakaya R; Ohira T; Matsuno R
Diabetes Obes Metab; 2015 Jul; 17(7):675-81. PubMed ID: 25787200
[TBL] [Abstract][Full Text] [Related]
8. Optimization of GPR40 Agonists for Type 2 Diabetes.
Liu JJ; Wang Y; Ma Z; Schmitt M; Zhu L; Brown SP; Dransfield PJ; Sun Y; Sharma R; Guo Q; Zhuang R; Zhang J; Luo J; Tonn GR; Wong S; Swaminath G; Medina JC; Lin DC; Houze JB
ACS Med Chem Lett; 2014 May; 5(5):517-21. PubMed ID: 24900872
[TBL] [Abstract][Full Text] [Related]
9. GPR40 (FFAR1) - Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo.
Hauge M; Vestmar MA; Husted AS; Ekberg JP; Wright MJ; Di Salvo J; Weinglass AB; Engelstoft MS; Madsen AN; Lückmann M; Miller MW; Trujillo ME; Frimurer TM; Holst B; Howard AD; Schwartz TW
Mol Metab; 2015 Jan; 4(1):3-14. PubMed ID: 25685685
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of G-protein-coupled receptor 40 enhances the mitogenic response to epoxyeicosatrienoic acids.
Ma SK; Wang Y; Chen J; Zhang MZ; Harris RC; Chen JK
PLoS One; 2015; 10(2):e0113130. PubMed ID: 25679385
[TBL] [Abstract][Full Text] [Related]
11. Activity of dietary fatty acids on FFA1 and FFA4 and characterisation of pinolenic acid as a dual FFA1/FFA4 agonist with potential effect against metabolic diseases.
Christiansen E; Watterson KR; Stocker CJ; Sokol E; Jenkins L; Simon K; Grundmann M; Petersen RK; Wargent ET; Hudson BD; Kostenis E; Ejsing CS; Cawthorne MA; Milligan G; Ulven T
Br J Nutr; 2015 Jun; 113(11):1677-88. PubMed ID: 25916176
[TBL] [Abstract][Full Text] [Related]
12. Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist.
Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Hirouchi M; Yoneyama T; Ito S; Toda N
ACS Med Chem Lett; 2015 Mar; 6(3):266-70. PubMed ID: 25815144
[TBL] [Abstract][Full Text] [Related]
13. Treatment of type 2 diabetes by free Fatty Acid receptor agonists.
Watterson KR; Hudson BD; Ulven T; Milligan G
Front Endocrinol (Lausanne); 2014; 5():137. PubMed ID: 25221541
[TBL] [Abstract][Full Text] [Related]
14. Improving the Pharmacokinetics of GPR40/FFA1 Full Agonists.
Du X; Dransfield PJ; Lin DC; Wong S; Wang Y; Wang Z; Kohn T; Yu M; Brown SP; Vimolratana M; Zhu L; Li AR; Su Y; Jiao X; Liu JJ; Swaminath G; Tran T; Luo J; Zhuang R; Zhang J; Guo Q; Li F; Connors R; Medina JC; Houze JB
ACS Med Chem Lett; 2014 Apr; 5(4):384-9. PubMed ID: 24900845
[TBL] [Abstract][Full Text] [Related]
15. GPCRs involved in metabolic diseases: pharmacotherapeutic development updates.
Jin C; Chen H; Xie L; Zhou Y; Liu LL; Wu J
Acta Pharmacol Sin; 2024 Jul; 45(7):1321-1336. PubMed ID: 38326623
[TBL] [Abstract][Full Text] [Related]
16. How Arrestins and GRKs Regulate the Function of Long Chain Fatty Acid Receptors.
Alharbi AG; Tobin AB; Milligan G
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293091
[TBL] [Abstract][Full Text] [Related]
17. Small molecule photocatalysis enables drug target identification via energy transfer.
Trowbridge AD; Seath CP; Rodriguez-Rivera FP; Li BX; Dul BE; Schwaid AG; Buksh BF; Geri JB; Oakley JV; Fadeyi OO; Oslund RC; Ryu KA; White C; Reyes-Robles T; Tawa P; Parker DL; MacMillan DWC
Proc Natl Acad Sci U S A; 2022 Aug; 119(34):e2208077119. PubMed ID: 35969791
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic Studies on the Stereoselectivity of FFAR1 Modulators.
Teng D; Zhou Y; Tang Y; Liu G; Tu Y
J Chem Inf Model; 2022 Aug; 62(15):3664-3675. PubMed ID: 35877470
[TBL] [Abstract][Full Text] [Related]
19. Free fatty acid receptor 1: a ray of hope in the therapy of type 2 diabetes mellitus.
Arora A; Behl T; Sehgal A; Singh S; Sharma N; Chigurupati S; Kaur R; Bhatia S; Al-Harrasi A; Vargas-De-La-Cruz C; Bungau S
Inflammopharmacology; 2021 Dec; 29(6):1625-1639. PubMed ID: 34669065
[TBL] [Abstract][Full Text] [Related]
20. Strained contacts with the cell membrane may influence ligand affinity to G protein coupled receptors: a case of free fatty acid receptor 1 agonists.
Lukin A; Bakholdina A; Chudinov M; Onopchenko O; Zhuravel E; Zozulya S; Gureev M; Krasavin M
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1651-1658. PubMed ID: 34294008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
